Restoring brain immune balance opens new avenue for Alzheimer's treatment
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Professor Minah Suh of the Department of Biomedical Engineering at Sungkyunkwan University, in collaboration with the biotechnology company IMNEWRUN and Professor Ho-Keun Kwon's team at Yonsei University College of Medicine, has identified a mechanism by which modulating an immune protein in the brain can restore a disrupted brain immune environment and reduce abnormally elevated neuronal activity in an animal model of Alzheimer's disease.
The findings provide scientific evidence supporting brain immune modulation as a potential therapeutic strategy for Alzheimer's disease, a major neurodegenerative disorder. The study was published in the journal Science Advances.
Alzheimer's disease is characterized not only by the accumulation of harmful protein deposits in the brain but also by dysfunction of cells that help maintain and protect the brain environment. In particular, microglia, the brain's resident immune cells, rapidly respond to tissue damage and help maintain the surrounding environment.
In Alzheimer's disease, however, normal microglial responsiveness is impaired, while neurons can exhibit abnormally increased activity.
The research team focused on the immune-regulatory proteins PD-1 and PD-L1, which have been widely studied in cancer immunotherapy. In Alzheimer's disease model mice, the researchers found increased PD-1 expression in microglia and increased PD-L1 expression in astrocytes, which play an important role in maintaining the brain environment. The team then investigated how these changes in immune-regulatory signaling affect brain function.
Testing PD-L1 blockade
To address this question, the researchers directly administered an antibody that blocks PD-L1 activity into the brains of Alzheimer's disease model mice and observed the responses using advanced microscopy techniques that enable visualization of living brain cells.
The results showed that the impaired response of microglia to sites of tissue damage was restored following PD-L1 blockade, while the abnormally elevated activity of neurons was also reduced. The researchers further found that these effects were more pronounced when PD-L1 was directly modulated within the brain than when the antibody was administered systemically.
Suh said, "This study reveals that disruption of immune-regulatory signaling in the Alzheimer's disease brain is closely associated with both impaired microglial function and abnormal neuronal activity. Our findings suggest that precisely modulating immune proteins within the brain could provide a new therapeutic strategy for Alzheimer's disease."
Publication details
Taeyoung Park et al, Targeting glial PD-1/PD-L1 restores microglial homeostasis and reduces neuronal hyperactivity in an Alzheimer's disease model, Science Advances (2026). DOI: 10.1126/sciadv.adx0731
Journal information: Science Advances
Key medical concepts
Alzheimer's DiseaseMicrogliaPDCD1 protein, human
Clinical categories
NeurologyAllergy and immunology Provided by Sungkyunkwan University Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Restoring brain immune balance opens new avenue for Alzheimer's treatment (2026, September 21) retrieved 22 September 2026 from https://medicalxpress.com/news/2026-09-brain-immune-avenue-alzheimer-treatment.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.